• Vincenzo Cantaluppi, Barbara Assenzio, Daniela Pasero, Giuseppe Mauriello Romanazzi, Alfonso Pacitti, Giacomo Lanfranco, Valeria Puntorieri, Erica L Martin, Luciana Mascia, Gianpaola Monti, Giampaolo Casella, Giuseppe Paolo Segoloni, Giovanni Camussi, and V Marco Ranieri.
• Dipartimento di Medicina Interna, Centro Ricerca Medicina Sperimentale (CeRMS), Torino, Italy.
• Intensive Care Med. 2008 Sep 1;34(9):1638-45.

ObjectiveTo test the hypothesis that extracorporeal therapy with polymyxin B (PMX-B) may prevent Gram-negative sepsis-induced acute renal failure (ARF) by reducing the activity of proapoptotic circulating factors.SettingMedical-Surgical Intensive Care Units.Patients And InterventionsSixteen patients with Gram-negative sepsis were randomized to receive standard care (Surviving Sepsis Campaign guidelines) or standard care plus extracorporeal therapy with PMX-B.Measurements And ResultsCell viability, apoptosis, polarity, morphogenesis, and epithelial integrity were evaluated in cultured tubular cells and glomerular podocytes incubated with plasma from patients of both groups. Renal function was evaluated as SOFA and RIFLE scores, proteinuria, and tubular enzymes. A significant decrease of plasma-induced proapoptotic activity was observed after PMX-B treatment on cultured renal cells. SOFA and RIFLE scores, proteinuria, and urine tubular enzymes were all significantly reduced after PMX-B treatment. Loss of plasma-induced polarity and permeability of cell cultures was abrogated with the plasma of patients treated with PMX-B. These results were associated to a preserved expression of molecules crucial for tubular and glomerular functional integrity.ConclusionsExtracorporeal therapy with PMX-B reduces the proapoptotic activity of the plasma of septic patients on cultured renal cells. These data confirm the role of apoptosis in the development of sepsis-related ARF.

34 keywords...

hide…